Targeted Disruption of E6/p53 Binding Exerts Broad Activity and Synergism with Paclitaxel and Topotecan against HPV-Transformed Cancer Cells
High-risk human papillomaviruses (HR-HPV) are the etiological agents of almost all cervical cancer cases and a high percentage of head-and-neck malignancies. Although HPV vaccination can reduce cancer incidence, its coverage significantly differs among countries, and, therefore, in the next decades...
Main Authors: | Marta Celegato, Lorenzo Messa, Chiara Bertagnin, Beatrice Mercorelli, Arianna Loregian |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/1/193 |
Similar Items
-
The Dimeric Form of HPV16 E6 Is Crucial to Drive YAP/TAZ Upregulation through the Targeting of hScrib
by: Lorenzo Messa, et al.
Published: (2021-08-01) -
Anti-tumor Synergistic Effect of a Dual Cancer-Specific Recombinant Adenovirus and Paclitaxel on Breast Cancer
by: Jing Wang, et al.
Published: (2020-03-01) -
Marine Sulfated Polysaccharide PMGS Synergizes with Paclitaxel in Inhibiting Cervical Cancer In Vitro
by: Xuan Xia, et al.
Published: (2023-04-01) -
Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system
by: A. G. Kedrova, et al.
Published: (2019-11-01) -
Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells
by: Jin Niu, et al.
Published: (2020-10-01)